AMARILLO BIOSCIENCES INC. APPOINTS

Thomas W. D'Alonzo to Board of Directors 
Business Editors 
AMARILLO, Texas--(BUSINESS WIRE)--March 20, 1997--Amarillo
Biosciences Inc. (NASDAQ:AMAR) announced today the appointment of
Thomas W. D'Alonzo (53) to its Board of Directors. 
D'Alonzo is president and chief operating officer of PPD Pharmaco
Inc., a global contract research organization headquartered in
Wilmington, N.C.  Previously he had been president of Genvec Inc., a
gene therapy biotechnology company.  He is a former president of
Glaxo Inc. where he spearheaded the company's impressive growth in
sales and profits, with Zantac sales passing the $1 billion mark.
D'Alonzo holds a law degree from the University of Denver College of
Law and a B.S. in Business administration from the University of
Delaware. 
In announcing the appointment, Joseph Cummins, President and
Chief Executive Officer of Amarillo, said, "We are pleased with
the addition of Tom D'Alonzo to our Board.  Mr. D'Alonzo brings with
him a significant understanding of the biotech industry.  We
believe his guidance as a Board Member will be instrumental in
helping us to achieve our overall strategic goals." 
Amarillo Biosciences Inc. is one of the leading companies
developing oral interferon alpha as a treatment of a variety of
diseases including oral mucositis in cancer patients, Hepatitis B,
Hepatitis C and Sjogren's Syndrome.
 
 
Press spacebar to pause and continue. Press esc to stop.